Glucotrack, Inc.: Ayrton Capital LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Ayrton Capital LLC disclosed a stake exceeding 5% in Glucotrack, Inc. via a Schedule 13G filing with the SEC (accession 0001493152-26-051279). The exact share count and percentage were not specified in the filing headline. The disclosure signals new institutional interest in the small-cap continuous glucose monitoring developer. Investors will watch for further detail on the position's size and any subsequent 13D or amendment filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Glucotrack, Inc., Ayrton Capital LLC